Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch [Seeking Alpha]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Seeking Alpha
CASGEVY revenue recognition is delayed due to Vertex's cost recoupment, but patient infusions are accelerating and geographic expansion continues. CRSP's pipeline focus shifts to CTX310 for dyslipidemia and CTX611 siRNA for VTE prophylaxis, with Phase 2 TKA data for 611 as a major 2026 catalyst. Despite $1.98B in cash affording 3-4 years of runway, CRSP must deliver breakthrough results in crowded markets to justify R&D intensity and achieve breakeven. J Studios/DigitalVision via Getty Images Overview I've covered CRISPR Therapeutics ( CRSP ) for quite a while now. Until just recently, my focus has predominantly been on its ex vivo sickle cell disease gene therapy product, CASGEVY, which it co-markets with Vertex Pharmaceuticals ( This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, a
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3Business Wire
- Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $441.00 price target on by analysts at Canaccord Genuity Group Inc..MarketBeat
- Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $591.00 price target on by analysts at HC Wainwright.MarketBeat
- Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- VRTX's page on the SEC website